Search NLS News

One of Nobel Laureate David Julius’ greatest joys is when people in his lab show him exciting data and make their own discoveries, and as a scientist and educator his goal is to bring society back to fact-based thinking. The mechanisms humans use to detect and process hot and cold and experience pain have not […]

Elekta has entered into a collaborative agreement with IBA to optimize quality assurance (QA) solutions. Radiation therapy departments and clinics using Elekta’s treatment delivery systems will benefit from QA solutions that are designed for these devices by streamlining workflows and improving access to measurement data, states Elekta “With this agreement, IBA will provide dosimetric QA […]

CardiNor has announced that it has achieved CE marking according to IVDD for the CardiNor Secretoneurin ELISA test. This new frontline biomarker for cardiovascular disease reflects the biological mechanism triggering arrhythmia. CardiNor has a clinical program to further strengthen and widening the clinical documentation of its novel biomarker, and the CardiNor Secretoneurin (SN) test is […]

UNION therapeutics has announced that the first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis. In November 2020, the US Food and Drug Administration (FDA) approved UNION’s Investigational New Drug Program (IND) for advancing oral orismilast into […]

Researchers at FIMM have developed a computational approach that can automatically identify various cell types based on single-cell RNA-sequencing data. The method has a huge potential for unbiased profiling of mixtures of cells, both for large-scale projects and samples derived from a single patient, states the researchers. It is not yet known how many different […]

The Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation have announced an initial commitment of up to 90 million USD of coordinated funding toward Pandemic Antiviral Discovery (PAD). PAD is a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access as a core […]

The Board of Directors of SyntheticMR has resolved to carry out a directed new issue of 1,250,000 shares, at a subscription price of SEK 48 per share, entailing proceeds of SEK 60 million before transaction costs. The Directed Share Issue was oversubscribed and a number of Swedish and international institutional investors, including certain existing shareholders, […]

Gilde Healthcare has raised 517 million EUR towards the first and final close of Gilde Healthcare Private Equity IV (GHPE IV). GHPE IV focuses on investments in profitable healthcare companies operating in the lower mid-market in North-west Europe. The fund concentrates on firms with an active buy-and-build strategy and invests in all sub-segments of the […]

The Norwegian healthtech company Otivio has extended an exploratory clinical trial with Neuro-SysMed to confirm the potential of its FlowOx medical device to alleviate multiple sclerosis symptoms. The trial follows a recent case series of 7 people with MS (pwMS) conducted by neurologist Dr Gabriela Fortes where FlowOx significantly alleviated MS related spasticity and pain, […]

AstraZeneca and MSD’s Lynparza has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. The approval by the US Food and Drug Administration (FDA) was based on results from the OlympiA Phase III […]